CLOs on the Move

Proclara Biosciences

www.proclarabio.com

 
Proclara is pioneering a new approach to treating neurodegenerative diseases. By developing novel therapies that recognize and target multiple misfolded proteins, we aim to make a transformative impact on the lives of patients affected by Alzheimer`s, Parkinson`s, and other diseases caused by protein misfolding. Our approach is shaped by an experienced team with deep drug development experience, and productive collaborations with world-class advisors and partners.
  • Number of Employees: 0-25
  • Annual Revenue: $0-1 Million

Executives

Name Title Contact Details

Similar Companies

Synchem

Synchem, Inc. is a Elk Grove Village, IL-based company in the Healthcare, Pharmaceuticals, & Biotech sector.

resTORbio

resTORbio, Inc. is a clinical stage company, developing medicines to treat aging-related diseases and conditions. resTORbio`s lead program targets the mechanistic target of rapamycin complex 1 (mTORC1) pathway to treat aging-related diseases and conditions. Initially, resTORbio is focused on developing medicines that address conditions caused by immunosenescence, the decline in immune function due to aging. resTORbio has initiated a Phase 2b trial for its lead product candidate, RTB101, evaluating its potential to reduce the incidence of respiratory tract infections (RTI) in elderly individuals at increased risk of RTI-related morbidity and mortality. resTORbio`s lead program is built upon two Phase 2a clinical studies demonstrating promising safety and efficacy results in almost 500 elderly individuals.

AmacaThera

AmacaThera is a Toronto-based biotechnology company focused on developing and commercializing a unique, injectable hydrogel platform technology for a wide range of medical applications.

Providence Therapeutics

Providence is a clinical-stage biotechnology company pioneering mRNA therapeutics and vaccines with a focus on infectious diseases and oncology. Initially founded as a cancer vaccines company in 2015, in response to a worldwide need for a COVID-19 vaccine, Providence expanded its focus beyond oncology therapies to develop an mRNA vaccine for COVID-19. Providence works with multiple industry collaborators, universities, nongovernmental agencies and multiple arms of the Government of Canada to discover and develop vaccines and treatments for infectious diseases and cancer. This has resulted in the development of an mRNA vaccine platform that includes a proprietary design algorithm and proprietary, scalable manufacturing processes.

ROME Therapeutics

ROME Therapeutics is developing novel therapies for cancer and autoimmune diseases by harnessing the power of the repeatome – vast stretches of uncharted genetic material that have long been dismissed as “junk DNA.”